Centessa Shareholders Approve Acquisition by Eli Lilly Subsidiary

On June 12, 2026, Centessa Pharmaceuticals plc announced that its shareholders overwhelmingly approved the acquisition of the company by LDH XV Corporation, a direct wholly owned subsidiary of Eli Lilly and Company. The transaction is being executed via a court-sanctioned scheme of arrangement under the United Kingdom Companies Act 2006. At the Scheme Meeting, approximately 99.98% of the voting shares (126,653,456 shares) were cast in favor of the proposal. Additionally, at a concurrent General Meeting, shareholders authorized the board to take necessary actions to implement the acquisition and approved amendments to the Company Articles. The acquisition remains subject to sanction by the High Court of Justice of England and Wales. A Court Sanction Hearing is currently scheduled for June 22, 2026. Separately, the company held its 2026 Annual General Meeting where all director nominees were re-appointed and statutory auditors were ratified. Centessa noted it is not subject to the UK Takeover Code, meaning no dealing disclosures under Rule 8 are required.